Résistance primaire et secondaire de Mycobacterium tuberculosis complex en France
Primary and secondary resistance of Mycobacterium tuberculosis complex in France
Réseau AZAY-Mycobactéries en 2017
Nouveaux casNew cases
Déjà traitésPreviously treated
39.2
R (%) à ≥ 1 antituberculeuxR to ≥ 1 drug
34.9
11.6 8.2 13.4 20.0
Total France* Autres Pays* Total France Autres Pays(* nés en / born in)
Rifampicine
MDR
Isoniazide
Résistance (%)
1.9
1.8
PrimairePrimary (new cases)
1.2
1.4
7.2
5.6
LOREM IPSUM DOLOR
SecondaireSecondary (treated cases)
27.5
4.0
4.0
25.5
16.0
32.4
Proportion of resistance in 2017
Evolution du réseau / Evolution of the network
2010
2017
2000
1995
2015
2005
Participants
AZAY-Mycobactéries
CNR Mycobactéries
Created on April 11, 2019
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Akihabara Connectors Infographic
View
Essential Infographic
View
Practical Infographic
View
Akihabara Infographic
View
Vision Board
View
The Power of Roadmap
View
Artificial Intelligence in Corporate Environments
Explore all templates
Transcript
Résistance primaire et secondaire de Mycobacterium tuberculosis complex en France
Primary and secondary resistance of Mycobacterium tuberculosis complex in France
Réseau AZAY-Mycobactéries en 2017
Nouveaux casNew cases
Déjà traitésPreviously treated
39.2
R (%) à ≥ 1 antituberculeuxR to ≥ 1 drug
34.9
11.6 8.2 13.4 20.0
Total France* Autres Pays* Total France Autres Pays(* nés en / born in)
Rifampicine
MDR
Isoniazide
Résistance (%)
1.9
1.8
PrimairePrimary (new cases)
1.2
1.4
7.2
5.6
LOREM IPSUM DOLOR
SecondaireSecondary (treated cases)
27.5
4.0
4.0
25.5
16.0
32.4
Proportion of resistance in 2017
Evolution du réseau / Evolution of the network
2010
2017
2000
1995
2015
2005
Participants